Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Experience in combined treatment of macular degeneration with microimpulse laser coagulation of macular drusen and intravitreal administration of a drug

Poster Details

First Author: K.Protasova RUSSIA

Co Author(s):    L. Ramazanova   O. Napylova   R. Shamratov   E. Pavlova   E. Yazykova   N. Pateeva     

Abstract Details

Purpose:

To evaluate the effectiveness of combined treatment of macular degeneration with microimpulse laser coagulation of macular drusen and intravitreal administration of ranibizumab.

Setting:

CHUZ Medical and sanitary part of ophthalmology department Astrakhan

Methods:

In the ophthalmologic department of the Chuz MCH Astrakhan, the patient turned 62. Complaints: image distortion, loss of vision. Visus OD / OS 0.7 / 0.7. According to the results: OST-ONE, photographic registration of the retina -multiplier soft discharge druses in the macular and paramacular zone. Two sessions were performed with focal laser coagulation of drusen and 2 sessions of micropulse laser treatment of RPE, intravitreal administration of ranibizumab OD, OS 3 injections.

Results:

On examination during the follow-up visit after OCT treatment (optical coherence tomography of the retina), a decrease in the area of �â�€�‹�â�€�‹the ONES (detachment of the non-epileptic retina), fit of the foveolar fossa, and normalization of its architecture were revealed. With photographic registration of the retina, there was a significant decrease in the number and area of �â�€�‹�â�€�‹retinal druses. Visual acuity of the right and left eyes 1.0. Patient noted increased visual acuity, lack of metamorphosis.

Conclusions:

Soft druses of large size are one of the main risk factors for the development of choroidal neovascularization and geographical atrophy. The combined treatment of macular drusen led to their regression, increased visual acuity, which is an effective method of treatment in this case.

Financial Disclosure:

travel has been funded, fully or partially, by a competing company

Back to Poster listing